chevron_leftBack
As of 24 April 2025, Veracyte, Inc. has a market cap of $2.45B USD, ranking #4679 globally and #1332 in the United States. It ranks #418 in the Healthcare sector, and #34 in the Diagnostics & Research industry.
Key Stats
Market Cap
$2.45BUSD
Enterprise Value
$2.21BUSD
Revenue (TTM)
$445.76MUSD
EBITDA (TTM)
$50.24MUSD
Net Income (TTM)
$24.14MUSD
EBITDA Margin
11%
Profit Margin
5.4%
PE Ratio
101.5
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Marc Stapley
open_in_new
Employees
824
Founded
2006
IPO
30 Oct 2013
Website
veracyte.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 1.1% | -0.2% | -1.1% | -27% | -3.5% | 59% |
Upcoming Earnings
Earnings Date
Wed, May 7
Earnings Time
bedtime
After Close
EPS Estimate
$0.2000
Revenue Estimate
$110.73M
14% yoy
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
VCYT
Veracyte Inc
ISIN: US92337F1075
Shares Out.:
Shares Outstanding:
77.945M1
Shares Float:
76.842M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
31.47 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Veracyte, Inc.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
